Boston Scientific Corp. - BSX STOCK NEWS

Boston Scientific Corporation reported net sales of $3.389 billion for Q1 2023, a rise of 12.0% year-over-year, exceeding guidance of 3-5%. The company achieved a GAAP net income of $300 million or $0.21 per share, up from $97 million or $0.07 per share in the prior year. Adjusted EPS was $0.47, surpassing guidance of $0.42 to $0.44. Key growth areas included U.S. sales with a 12.7% increase, and 20.2% growth in emerging markets. The company introduced several innovative medical devices, including the LithoVue™ Elite and POLARx™ FIT systems. Full-year sales growth is projected at 8.5% to 10.5%, with adjusted EPS expected between $1.90 to $1.96. A conference call will provide further insights.

Boston Scientific Corporation (NYSE:BSX) released its 2022 Performance Report, highlighting advancements in medical technologies alongside environmental and social governance (ESG) commitments. The company invested over $1.3 billion in R&D and improved the lives of 33 million patients globally. Among key achievements, it became one of the first in its sector to have a net-zero target approved under the Science Based Targets initiative. Boston Scientific reached 76% renewable electricity usage and is on track for carbon neutrality by 2030. The report also showcased progress in diversity, with 42.6% of managerial roles held by women. The company emphasized its commitment to sustainability and social equity while delivering improved operational capabilities.

Boston Scientific emphasizes the importance of diversity, equity, and inclusion (DEI) as a business imperative in the medical device industry. After evaluating employee feedback in 2017, leadership recognized that many female employees felt overlooked for promotions compared to their male counterparts. This realization prompted a commitment to improve DEI within the organization, as fostering a diverse workplace enhances innovation and problem-solving capabilities. The company believes that understanding the unique challenges faced by patients and customers requires diverse perspectives, ultimately driving creativity in product development.

Boston Scientific emphasizes its commitment to improving lives through innovative deep brain stimulation (DBS) products, particularly for patients with Parkinson's disease (PD). The company showcases the passion of its employees, such as Nicky Nault, who personally connects with patients, and Celine Constant, who empowers PD patients through education. Benny Yeh leads the R&D division, ensuring that all DBS products meet high-quality standards. The firm supports Parkinson's Awareness Month by highlighting these employees' stories, illustrating their dedication to patient care. DBS therapy aims to reduce medication needs and improve motor functions for PD patients, enhancing their quality of life.

Boston Scientific Corporation (NYSE: BSX) will hold a conference call on April 26, 2023, at 8:00 a.m. EDT, to discuss its first-quarter financial results for the period ending March 31, 2023. The call will feature Mike Mahoney, CEO, and Dan Brennan, CFO. A news release detailing the financial results will be issued prior to the call on the same day. Investors can access the live webcast and replay on Boston Scientific's investor relations website. This event marks Boston Scientific's ongoing commitment to transparency and communication with stakeholders.